Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1946 1
1950 3
1951 6
1952 3
1953 1
1954 4
1955 8
1956 4
1958 5
1959 6
1960 4
1961 8
1962 4
1963 9
1964 16
1965 6
1966 14
1967 16
1968 24
1969 13
1970 23
1971 19
1972 13
1973 23
1974 18
1975 26
1976 17
1977 11
1978 21
1979 18
1980 15
1981 4
1982 4
1983 3
1984 5
1985 5
1986 7
1987 8
1988 16
1989 13
1990 13
1991 12
1992 7
1993 6
1994 5
1995 5
1996 8
1997 15
1998 22
1999 16
2000 21
2001 29
2002 47
2003 57
2004 51
2005 79
2006 83
2007 91
2008 97
2009 91
2010 105
2011 124
2012 106
2013 111
2014 150
2015 189
2016 191
2017 210
2018 241
2019 242
2020 219
2021 281
2022 281
2023 248
2024 77

Text availability

Article attribute

Article type

Publication date

Search Results

3,559 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Belyatsky
Page 1
Did you mean boris belitsky (35 results)?
Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D. Loukinov D. Cancer Immunol Immunother. 2018 Dec;67(12):1955-1965. doi: 10.1007/s00262-018-2251-8. Epub 2018 Nov 2. Cancer Immunol Immunother. 2018. PMID: 30390146 Review.
Recently CTCFL/BORIS has received additional attention as a target expressed in cancer stem cells (CSC). ...About 20% of CTCFL/BORIS immunized animals were tumor free. 50% of animals remained metastasis free. ...
Recently CTCFL/BORIS has received additional attention as a target expressed in cancer stem cells (CSC). ...About 20% of CTCFL/BOR
BORIS: a key regulator of cancer stemness.
Soltanian S, Dehghani H. Soltanian S, et al. Cancer Cell Int. 2018 Oct 5;18:154. doi: 10.1186/s12935-018-0650-8. eCollection 2018. Cancer Cell Int. 2018. PMID: 30323717 Free PMC article. Review.
BORIS (CTCFL) is a DNA binding protein which is involved in tumorigenesis. ...The following is a comprehensive review on contradictory views on the expression pattern and biological function of BORIS in normal, as well as cancer cells/tissues, and presents some evid
BORIS (CTCFL) is a DNA binding protein which is involved in tumorigenesis. ...The following is a comprehensive review on contradictor
In Memoriam: Boris N. Leibush.
Bondareva VM, Chistyakova OV, Gutierrez J. Bondareva VM, et al. Gen Comp Endocrinol. 2022 Nov 1;328:114117. doi: 10.1016/j.ygcen.2022.114117. Epub 2022 Aug 17. Gen Comp Endocrinol. 2022. PMID: 35987250 No abstract available.
BORIS in human cancers -- a review.
Martin-Kleiner I. Martin-Kleiner I. Eur J Cancer. 2012 Apr;48(6):929-35. doi: 10.1016/j.ejca.2011.09.009. Epub 2011 Oct 21. Eur J Cancer. 2012. PMID: 22019212 Review.
Re-expression of BORIS in cancers is due to the hypomethylation of its promoter. High expression of BORIS protein and RNA correlates with the tumour size and grade in cancer patients. ...BORIS antitumor vaccines have been tested in mice with several cancers, …
Re-expression of BORIS in cancers is due to the hypomethylation of its promoter. High expression of BORIS protein and RNA corr …
Boris Ephrussi.
Roman H. Roman H. Annu Rev Genet. 1980;14:447-50. doi: 10.1146/annurev.ge.14.120180.002311. Annu Rev Genet. 1980. PMID: 6782939 No abstract available.
Boris Yegorov.
Kyle RA, Shampo MA. Kyle RA, et al. JAMA. 1972 Oct 9;222(2):177. doi: 10.1001/jama.222.2.177. JAMA. 1972. PMID: 4560298 No abstract available.
CTCF and BORIS in genome regulation and cancer.
Marshall AD, Bailey CG, Rasko JE. Marshall AD, et al. Curr Opin Genet Dev. 2014 Feb;24:8-15. doi: 10.1016/j.gde.2013.10.011. Epub 2013 Dec 14. Curr Opin Genet Dev. 2014. PMID: 24657531 Review.
BORIS is aberrantly expressed frequently in cancer, leading some to propose a pro-tumourigenic role for BORIS. However, BORIS can inhibit cell proliferation, and is mutated in cancer similarly to CTCF suggesting BORIS activation in cancer may be due to
BORIS is aberrantly expressed frequently in cancer, leading some to propose a pro-tumourigenic role for BORIS. However, BOR
BORIS-mediated generation of circular RNAs induces inflammation.
Xu H, Fang M, Li C, Zuo B, Ren J, Zhang Y. Xu H, et al. Transl Oncol. 2022 Apr;18:101363. doi: 10.1016/j.tranon.2022.101363. Epub 2022 Feb 16. Transl Oncol. 2022. PMID: 35182955 Free PMC article.
However, the mechanism underlying the regulation of circRNAs by the oncoprotein BORIS and their role in regulating inflammation and immunity remain to be further explored. ...Thus, our study delineated the novel mechanism by which cancer-specific antigen BORIS regul …
However, the mechanism underlying the regulation of circRNAs by the oncoprotein BORIS and their role in regulating inflammation and i …
3,559 results